Sangon Biotech: difference between revisions
Diff·revision 27 → 28·17:02, 8 May 2025
Difference between revision 27 and revision 28 of Sangon Biotech. 2 lines changed; the page grew by 398 bytes.
| Revision 27 — 19:45, 1 May 2025 StubTagTeodor (talk) fix significant figures — source gives fewer 6,881 bytes ±0 | Revision 28 — 17:02, 8 May 2025 Chromatokid (talk) fix arithmetic in worked example 7,279 bytes +398 | ||
|---|---|---|---|
| 52 | Submitted reports on SGN peptide material to July 2026 are moderate in number. Reported [[Area percent purity|area percent]] figures have been high and consistent with accompanying certificates.{{r|reports}} | 52 | Submitted reports on SGN peptide material to July 2026 are moderate in number. Reported [[Area percent purity|area percent]] figures have been high and consistent with accompanying certificates.{{r|reports}} |
| 53 | 53 | ||
| + | 54 | Because the reagent business operates in a market with its own documentation conventions, purchasers have occasionally compared the two and found the reagent-line paperwork more standardised than the peptide-line paperwork.{{r|reports}} That comparison is within one organisation and is therefore more informative than a comparison across organisations, but it rests on a small number of reports. | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |